Cargando…

Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma: a systematic review and pooled analysis

Background: Weekly and triweekly cisplatin-based concurrent chemoradiotherapy (CCRT) have been used in the treatment of nasopharyngeal carcinoma (NPC). Objective: This study aimed to compare the benefits and risks between the two treatments. Methods: We systematically searched electronic databases f...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Jie, Zou, Guo-Rong, Li, Xiu-Wen, Su, Zhen, Cao, Xiao-Long, Wang, Bi-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425212/
https://www.ncbi.nlm.nih.gov/pubmed/34539894
http://dx.doi.org/10.7150/jca.62188
_version_ 1783749813010956288
author Tang, Jie
Zou, Guo-Rong
Li, Xiu-Wen
Su, Zhen
Cao, Xiao-Long
Wang, Bi-Cheng
author_facet Tang, Jie
Zou, Guo-Rong
Li, Xiu-Wen
Su, Zhen
Cao, Xiao-Long
Wang, Bi-Cheng
author_sort Tang, Jie
collection PubMed
description Background: Weekly and triweekly cisplatin-based concurrent chemoradiotherapy (CCRT) have been used in the treatment of nasopharyngeal carcinoma (NPC). Objective: This study aimed to compare the benefits and risks between the two treatments. Methods: We systematically searched electronic databases for prospective and retrospective clinical studies of NPC patients who received weekly compared with triweekly cisplatin-based CCRT. The primary endpoints comprised overall, failure-free, distant metastasis-free, and locoregional recurrence-free survivals (OS, FFS, DMFS, and LRFS). Secondary endpoints were toxicities. Results: Six studies were included in the systematic review, of which four with 1515 NPC patients were eligible for further pooled analysis. There were no significant differences between weekly and triweekly groups in terms of 5-year OS (odds ratio [OR] 0.95, 95% confidence interval [CI] 0.51-1.79), FFS (OR 1.09, 95% CI 0.67-1.76), DMFS (OR 1.25, 95% CI 0.54-2.92), and LRFS (OR 0.83, 95% CI 0.55-1.25). For grade ≥ 3 toxicities, the weekly group had higher risks of anemia (risk ratio [RR] 2.96, 95% CI 1.12-7.81) and thrombocytopenia (RR 2.75, 95% CI 1.54-4.90), but a lower incidence of vomiting (RR 0.34, 95% CI 0.18-0.63) versus the triweekly group. Conclusion and Relevance: Both weekly and triweekly schedules could be recommended to NPC patients during CCRT. Additionally, hematologic adverse events in weekly strategy and non-hematologic adverse events in triweekly strategy are of higher concern.
format Online
Article
Text
id pubmed-8425212
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-84252122021-09-16 Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma: a systematic review and pooled analysis Tang, Jie Zou, Guo-Rong Li, Xiu-Wen Su, Zhen Cao, Xiao-Long Wang, Bi-Cheng J Cancer Research Paper Background: Weekly and triweekly cisplatin-based concurrent chemoradiotherapy (CCRT) have been used in the treatment of nasopharyngeal carcinoma (NPC). Objective: This study aimed to compare the benefits and risks between the two treatments. Methods: We systematically searched electronic databases for prospective and retrospective clinical studies of NPC patients who received weekly compared with triweekly cisplatin-based CCRT. The primary endpoints comprised overall, failure-free, distant metastasis-free, and locoregional recurrence-free survivals (OS, FFS, DMFS, and LRFS). Secondary endpoints were toxicities. Results: Six studies were included in the systematic review, of which four with 1515 NPC patients were eligible for further pooled analysis. There were no significant differences between weekly and triweekly groups in terms of 5-year OS (odds ratio [OR] 0.95, 95% confidence interval [CI] 0.51-1.79), FFS (OR 1.09, 95% CI 0.67-1.76), DMFS (OR 1.25, 95% CI 0.54-2.92), and LRFS (OR 0.83, 95% CI 0.55-1.25). For grade ≥ 3 toxicities, the weekly group had higher risks of anemia (risk ratio [RR] 2.96, 95% CI 1.12-7.81) and thrombocytopenia (RR 2.75, 95% CI 1.54-4.90), but a lower incidence of vomiting (RR 0.34, 95% CI 0.18-0.63) versus the triweekly group. Conclusion and Relevance: Both weekly and triweekly schedules could be recommended to NPC patients during CCRT. Additionally, hematologic adverse events in weekly strategy and non-hematologic adverse events in triweekly strategy are of higher concern. Ivyspring International Publisher 2021-08-28 /pmc/articles/PMC8425212/ /pubmed/34539894 http://dx.doi.org/10.7150/jca.62188 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Tang, Jie
Zou, Guo-Rong
Li, Xiu-Wen
Su, Zhen
Cao, Xiao-Long
Wang, Bi-Cheng
Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma: a systematic review and pooled analysis
title Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma: a systematic review and pooled analysis
title_full Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma: a systematic review and pooled analysis
title_fullStr Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma: a systematic review and pooled analysis
title_full_unstemmed Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma: a systematic review and pooled analysis
title_short Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma: a systematic review and pooled analysis
title_sort weekly versus triweekly cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma: a systematic review and pooled analysis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425212/
https://www.ncbi.nlm.nih.gov/pubmed/34539894
http://dx.doi.org/10.7150/jca.62188
work_keys_str_mv AT tangjie weeklyversustriweeklycisplatinbasedconcurrentchemoradiotherapyfornasopharyngealcarcinomaasystematicreviewandpooledanalysis
AT zouguorong weeklyversustriweeklycisplatinbasedconcurrentchemoradiotherapyfornasopharyngealcarcinomaasystematicreviewandpooledanalysis
AT lixiuwen weeklyversustriweeklycisplatinbasedconcurrentchemoradiotherapyfornasopharyngealcarcinomaasystematicreviewandpooledanalysis
AT suzhen weeklyversustriweeklycisplatinbasedconcurrentchemoradiotherapyfornasopharyngealcarcinomaasystematicreviewandpooledanalysis
AT caoxiaolong weeklyversustriweeklycisplatinbasedconcurrentchemoradiotherapyfornasopharyngealcarcinomaasystematicreviewandpooledanalysis
AT wangbicheng weeklyversustriweeklycisplatinbasedconcurrentchemoradiotherapyfornasopharyngealcarcinomaasystematicreviewandpooledanalysis